Guardion® Receives approval from USPTO for expanded claims for its Proprietary Medical Device, the MAPCAT SF
23. Oktober 2019 07:00 ET
|
Guardion Health Sciences, Inc.
San Diego, California, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI) announced that it has received approval from the USPTO for...
Guardion Health Sciences Announces Pricing of $5.2 Million Underwritten Public Offering
13. August 2019 09:00 ET
|
Guardion Health Sciences, Inc.
San Diego, CA, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), announced the pricing of an underwritten public offering of 13,000,000...
Guardion Health Sciences Reports June 30, 2019 Interim Results of Operations
12. August 2019 08:40 ET
|
Guardion Health Sciences, Inc.
Highlights Include: 18.2% Revenue Growth for the Three Months Ended June 30, 2019 and 21.7% Revenue Growth for the Six Months Ended June 30, 2019 San Diego, CA , Aug. 12, 2019 (GLOBE...
Foundation Fighting Blindness selects Guardion’s VectorVision CSV-1000 Diagnostic Instrument for Use in Large-Scale Multi-Center Clinical Trial
06. August 2019 07:00 ET
|
Guardion Health Sciences, Inc.
The CSV-1000 Diagnostic Instrument is Considered the Standard of Care for the Measurement of Contrast Sensitivity San Diego, CA, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc....
Guardion’s Proprietary Medical Device, the MapcatSF®, Receives Patent from the Hong Kong Patents Registry
17. Juli 2019 07:00 ET
|
Guardion Health Sciences, Inc.
San Diego, CA, July 17, 2019 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), announced that it has received a patent from the Patents Registry in...
Guardion’s Proprietary Medical Device, the MapcatSF®, Receives Patent from the European Union
20. Juni 2019 07:00 ET
|
Guardion Health Sciences, Inc.
San Diego, CA, June 20, 2019 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), an ocular health sciences and technologies company that develops,...
Guardion Launches Second Ocular Health Formula ‘GlaucoCetin’
04. Juni 2019 07:00 ET
|
Guardion Health Sciences, Inc.
In an IRB-approved trial conducted at the New York Eye and Ear Infirmary, the parent compound of GlaucoCetin, GlaucoHealth, designed by Robert Ritch, MD, successfully reversed mitochondrial...